H.C. Wainwright raised the firm’s price target on Alpha Tau (DRTS) to $15 from $12 and keeps a Buy rating on the shares. The firm added potential sales of Alpha DaRT for recurrent glioblastoma into the model with a 60% probability of approval.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRTS:
- Alpha Tau Wiped Out Visible Tumors in Two of Three Brain Cancer Patients in Its First U.S. Trial
- Alpha Tau Medical Shares Interim U.S. Glioblastoma Trial Data for Alpha DaRT
- Alpha Tau announces interim data from REGAIN trial
- Alpha Tau Posts Strong Interim REGAIN Data in U.S. Recurrent Glioblastoma Trial
- Alpha Tau completes enrollment in ReSTART trial